Brokers Issue Forecasts for Bone Biologics Q1 Earnings

Bone Biologics Corp. (NASDAQ:BBLG) – Analysts at Zacks Research issued their Q1 2026 earnings per share (EPS) estimates for shares of Bone Biologics in a research report issued on Tuesday, March 3rd. Zacks Research analyst B. Sorensen forecasts that the company will earn ($0.54) per share for the quarter. The consensus estimate for Bone Biologics’ current full-year earnings is ($5.00) per share. Zacks Research also issued estimates for Bone Biologics’ Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.43) EPS and FY2027 earnings at ($1.62) EPS.

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Bone Biologics in a research note on Monday, December 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Bone Biologics Stock Down 0.6%

Shares of NASDAQ:BBLG opened at $1.25 on Wednesday. Bone Biologics has a 52-week low of $1.11 and a 52-week high of $6.75. The stock’s fifty day simple moving average is $1.47 and its 200-day simple moving average is $1.87. The company has a market capitalization of $2.25 million, a P/E ratio of -0.33 and a beta of 0.78.

Hedge Funds Weigh In On Bone Biologics

An institutional investor recently raised its position in Bone Biologics stock. DRW Securities LLC raised its stake in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the quarter. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 34.30% of the company’s stock.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.